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Abstract: Multiple locus typing based on sequencing heterologous regions in 26 open reading
frames (ORFs) of equine herpesvirus 1 (EHV-1) strains Ab4 and V592 was used to characterise 272
EHV-1 isolates from 238 outbreaks of abortion, respiratory or neurological disease over a 28-year
period. The analysis grouped the 272 viruses into at least 10 of the 13 unique long region (UL)
clades previously recognised. Viruses from the same outbreak had identical multi-locus profiles.
Sequencing of the ORF68 region of EHV-1 isolates from 222 outbreaks established a divergence
into seven groups and network analysis demonstrated that Irish genotypes were not geographically
restricted but clustered with viruses from all over the world. Multi-locus analysis proved a more
comprehensive method of strain typing than ORF68 sequencing. It was demonstrated that when
interpreted in combination with epidemiological data, this type of analysis has a potential role in
tracking virus between premises and therefore in the implementation of targeted control measures.
Viruses from 31 of 238 outbreaks analysed had the proposed ORF30 G2254/D752 neuropathogenic
marker. There was a statistically significant association between viruses of the G2254/D752 genotype
and both neurological disease and hypervirulence as defined by outbreaks involving multiple abortion
or neurological cases. The association of neurological disease in those with the G2254/D752 genotype
was estimated as 27 times greater than in those with the A2254/N752 genotype.
Keywords: EHV-1; multi-locus typing; ORF68; neuropathogenic marker
1. Introduction
Equid alphaherpesvirus 1 (EHV-1) commonly known as equine herpesvirus 1, is the most
economically and clinically significant equine herpesvirus [1]. EHV-1 belongs to the Alphaherpesvirinae
subfamily, genus Varicellovirus [2]. The virus has a global distribution in horse populations,
causing several clinical syndromes including mild to severe respiratory disease, abortion, neonatal
foal death, chorioretinitis, and neurological disorders often referred to as equine herpesvirus
myeloencephalopathy (EHM) [3–6]. The neurological form of the disease is less common than
abortion or respiratory disease but can result in fatalities [6]. Primary infection occurs via the
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respiratory epithelium by close contact with infectious animals and inhalation of virus, or in rare cases
contaminated feed and water [7,8]. Infection is followed by a cell associated viraemia that is central to
the virus spreading to secondary sites of infection [9,10]. EHM results from the inflammatory response
to infection of the vascular endothelium of arteries in the central nervous system (CNS), leading to local
haemorrhage, thrombosis, and ischaemia [11]. The occurrence of an increase in devastating outbreaks
of EHM throughout North America and Europe in 2006 and 2007 led to its classification as a potentially
emerging disease by the U.S. Department of Agriculture’s Animal and Health Inspection Service [12].
EHV-1 is a World Organisation for Animal Health (OIE) listed disease which must be notified to OIE
so that appropriate action can be taken to ensure safe international trade in horses [13].
The EHV-1 genome consists of a linear molecule of double stranded DNA, approximately 150 kbp
in length [14]. The genome is composed of a unique long (UL) region and a unique short (US) region.
These genomic segments are flanked by inverted repetitive elements called terminal (TRL and TRS)
and internal (IRL and IRS) repeats. Traditionally, the genome is separated into 80 open reading frames
that encode 76 distinct proteins and four repeated ones. To date, 28 complete EHV-1 genomes isolated
from the domestic horse are available in GenBank. Recently the complete genome sequencing of the
attenuated Kentucky A strain (KyA) a candidate vaccine strain, revealed two additional open reading
frames (ORFs) in the internal repeat region (IR2 and IR3; ORFs 77 and 78) that are conserved in the
virulent RacL11 and Ab4 strains [15].
Experimental infections demonstrated that different strains of EHV-1 vary in their abortigenic
potential and in their neuropathogenicity [16–19]. EHV-1 strain Ab4 isolated from a quadriplegic
gelding was associated with severe clinical disease including neurological disease and frequent
abortion [3]. In contrast, strain V592, isolated from a foetus during a large abortion storm [20], appears
to be less virulent on experimental infection, resulting in low levels of viraemia, few cases of abortion,
and no neurological disease [16,18].
The availability of the genome sequences of Ab4 [14] and V592 [21] encouraged efforts to
define the determinants of neuropathogenicity. Forty-two amino acid residue differences across
31 ORFs were identified and a single nucleotide polymorphism (SNP) within the polymerase
gene (causing a substitution of asparagine (N) to aspartic acid (D) at amino acid position 752 of
ORF30) was found to be strongly associated with the occurrence of EHV-1 neurological disease [21].
Subsequently experimental infection with recombinant viruses with differing polymerase sequences
supported the link between the G2254/D752 genotype and neuropathogenicity [22,23]. However other
international studies of field isolates yielded conflicting results and indicated that this association was
not definitive [24–27].
Nugent et al. (2006) [21] also proposed that a short region spanning approximately 600 bp of
ORF68, which encodes virion protein US2 [28], was a primary strain marker for classifying EHV-1 field
isolates into six groups [21]. However, there have been conflicting conclusions regarding the usefulness
of this approach for molecular tracking of EHV-1 in other countries suggesting that it may not be an
effective substitute for more detailed sequence analysis [24,29–33].
A recent study which included the next generation sequencing of 78 EHV-1 strains (the majority
of which originated in the United Kingdom (UK)) and phylogenetic analysis with 26 EHV-1 genome
sequences from the United States and Australia [34] suggested that EHV-1 has diverged into 13 distinct
UL clades [35]. The study concluded that abortion isolates grouped into nine and neurological isolates,
most of which had the G2254/D752 substitution, grouped into five of the 13 clades.
The aim of this study was to analyse and classify EHV-1 strains collected from outbreaks of
non-neurological (respiratory disease, abortion and neonatal foal death) and neurological disease in
the Irish horse population over three decades. Three isolates from two severe abortion outbreaks in
Italy were also included. EHV-1 isolates from 238 outbreaks were characterised based on multi-locus
profiling and single representatives from 222 of the 238 outbreaks were further characterised by
ORF68 sequencing. Isolates from non-neurological and neurological disease outbreaks in addition to
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Phylogenetic analysis (see tree in Figure 1 and alignment in Supplementary Figure S1) was
performed using an artificial peptide consisting of concatenated amino acids of UL and US based on 31
non-synonymous substitutions between Ab4 and V592 and seven additional mutations identified by
analysis of viruses characterised in this study and published sequences [34,35]. The analysis grouped
the 272 viruses characterised into 10 of the 13 UL clades identified by Bryant et al. (2018) [35]. This
approach did not distinguish the single clade 2 representative NY03, which grouped with clade 1
viruses or the single clade 12 representative Suffolk/91/94, which grouped with the clade 10 viruses.
Similar to the UK, the majority of Irish isolates (118 isolates from 106 outbreaks from 1991 to 2017)
clustered in clade 7 with viruses from the United States and Australia. No Irish viruses belonged to
clade 4, which contains the single representative strain RACL11.
One hundred and eleven viruses characterised in this study clustered in clades previously
restricted to UK isolates (see Table 1). Isolates from 14 outbreaks (1996 to 2016) clustered in clade 13
which previously had a single representative strain (Suff/123/2005). Isolates from 12 Irish outbreaks
(1990 to 2016) and an Italian isolate (2003) clustered with the UK clade 8 viruses, including NMKT04.
Other viruses clustered in clades with a wider global distribution, for example isolates from ten
outbreaks (eight in Ireland, two in Italy) from 1990 to 2016 clustered with Ab4 and other clade 1 viruses
from the UK, Australia, Japan, and Hong Kong. Isolates from 21 outbreaks (2005 to 2017) clustered
with clade 6 viruses from the UK, United States, New Zealand, and Australia. Two isolates clustered
in clade 3, which was previously restricted to Japanese and Australian isolates.
Table 1. Summary of multi-locus sequence typing results of the 272 equine herpesvirus 1 (EHV-1)
isolates characterised.
Abortion Neurological
UL Clade 1 Isolates Outbreaks Premises
ORF30
D752 3 Respiratory Single
4 Multiple 4 Single Multiple
1 13 10 9 8 0 4 2 1 3
3 2 2 2 1 0 1 0 1 0
5 3 2 2 0 0 1 1 0 0
6 25 21 21 0 1 19 * 1 1 * 0
7 118 106 104 5 1 80 19 5 1
8 14 13 13 14 0 7 4 0 2
9 25 22 22 2 0 16 5 0 1
10 19 16 15 0 0 12 3 1 0
11 38 32 32 3 1 23 4 2 2
13 15 14 14 2 0 8 4 0 2
Total 272 238 220 2 35 3 170 * 43 11 * 11
1 Unique long region (UL) clade number correlates to those previously described [35]. 2 Some premises experienced
outbreaks in different years. Outbreaks from a total of 220 premises were investigated. 3 Represents the number
of isolates with the putative neurological marker G2254/D752 in the polymerase catalytic subunit open reading
frame (ORF) 30 [21]. 4 Single is defined as one case on a premises. Multiple is defined as more than one case on
a premises. * One mare is categorised under single abortion and single neurological disease expression, as isolate
IRL/766/2008 was collected when she exhibited neurological signs and isolate IRL/155/2008 was collected from
her aborted foetus 11 weeks later.
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Figure 1. Maximum likelihood phylogenetic tree of 126 representative amino acid sequences based on
the Jones Taylor Thornton (JTT) matrix-based model. The sequences were constructed by concatenation
of 38 amino acids, 31 non-synonymous substitutions between Ab4 and V592, and seven additional
mutations identified in other EHV-1 strains. The tree is based on alignment of the artificial peptide
derived by multi-locus sequence typing of 94 EHV-1 isolates sequenced in this study and 32 EHV-1
strains obtained from GenBank with known UL clade grouping [35]. EHV-1 UL clades are indicated
by coloured continuous bars and are numbered according to the key. Details of the sequences are in
Supplementary Tables S1 and S2. The scale bar represents the number of substitutions per site. Bootstrap
values after 100 replications are indicated at major nodes. Asterisks denote neurological isolates.
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The number of viruses characterised, and the clades identified for each of the 28 years in the
study are summarised in Table 2. Co-circulation of clades was observed but some clades were only
identified sporadically. Clade 7 viruses predominated and were identified almost every year. Clades 1,
8, 9, 11 and 13 circulated in all three decades included in the study. In contrast, clade 3 and 5 viruses
were confined to 1992/93, and 2014/15 respectively. The clade 3 viruses were isolated on two separate
premises in the same county. Similarly, the clade 5 viruses were isolated within a 100-km radius.
This suggests that viruses of clades 3 and 5 may have a restricted distribution in Ireland and therefore
be easier to trace than viruses of more ubiquitous clades. There was no evidence of circulation of clade
10 and clade 6 strains prior to 2002 and 2005, respectively, but both persisted and were identified up
to 2017.






















1990 1 1 1 3
1991 2 2
1992 1 1 1 1 4
1993 1 1 1 3
1994 1 3 1 2 7
1995 1 2 1 4
1996 1 1 1 3
1997 3 2 5
1998 4 4
1999 3 1 1 5
2000 3 1 4
2001 1 2 2 5
2002 2 1 1 4
2003 2 1 3
2004 3 1 1 5
2005 2 2 17 3 3 3 30
2006 1 13 2 1 3 3 23
2007 1 7 3 1 1 13
2008 5 4 1 5 8 1 24
2009 1 1 7 2 11
2010 1 9 1 1 2 1 15
2011 2 5 1 1 3 12
2012 5 3 1 1 10
2013 5 1 2 2 1 11
2014 2 2 6 1 1 12
2015 1 1 2 8 1 1 4 18
2016 1 2 7 1 1 1 2 2 17
2017 3 10 2 15
Total 13 2 3 25 118 14 25 19 38 15 272
There were 29 premises from which more than one isolate was characterised by multi-locus typing
(see Supplementary Table S3). On two premises serial samples collected from the same horse had
identical multi-locus profiles. On premises 114 a mare aborted after recovering from neurological
disease and the clade 6 viruses isolated from her (IRL/766/2008) and her aborted foetus 10 weeks
(IRL/155/2008) later had identical profiles. Similarly, on premises 117, viruses isolated on three
separate occasions from a foal born with EHV-1 infection and treated with ganciclovir had identical
profiles. Furthermore, the profiles of viruses isolated from different horses during the same outbreak
on 15 premises were also identical. However, of 14 premises where outbreaks occurred in different
years the viruses isolated were only identical in four.
The potential usefulness of multi-locus analysis to corroborate or disprove a hypothesis based
on epidemiological data was demonstrated in selected outbreaks (see Supplementary Table S1).
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The hypothesis that multiple cases of neurological disease identified on two different sport horse
premises (141 and 142) were linked by horse movement was supported by the identical multi-locus
profiles of the viruses isolated (IRL/350/2011 and IRL/331/2011). Similarly, IRL/394/2009 was
isolated on premises 121 from a mare with neurological disease that had returned home from a public
stud farm, premises 122. Subsequent investigation indicated that IRL/394/2009 had an identical
multi-locus profile to virus IRL/626/2009, which was circulating sub-clinically on premises 122.
Multi-locus typing also corroborated the hypothesis that in one case of neurological disease the
source of virus was reactivation of a latent infection. The yearling of a mare that was present on
premises 1 during a severe neurological outbreak travelled to premises 22 the following year to be
castrated. A pony that shared a field with the yearling post castration, presented with neurological signs
approximately two weeks later. The virus isolated from the in-coordinate pony had the same genetic
profile as the viruses associated with EHV-1 outbreaks on premises 1, supporting the hypothesis that
reactivated virus from the yearling was the source of infection. In contrast, multi-locus typing provided
evidence to disprove the hypothesis that horse movement from premises 15 where IRL/176/1994
was isolated prior to diagnosis of EHV-1 abortion and multiple cases of neurological disease, was the
source of virus to a public stud (premises 16) where a single mare developed neurological disease.
However, the virus isolated IRL/206/1994 (clade 7) from the single case on the stud farm was readily
distinguishable from IRL/176/1994 (clade 11), indicating that premises 15 was highly unlikely to be
the source.
For routine molecular epidemiological investigation in a diagnostic laboratory alignment of
representative EHV-1 isolates from all clades (see Figure 2) identified that a limited number of
non-synonymous sites in six ORFs could be targeted to distinguish the clades identified in this study.
Clade 7, the most prominent clade circulating, is readily identified using ORF11 (R235M). The same
ORF can be used to identify clade 9 viruses. ORF13 identifies clades 6 and 8 using non-synonymous
changes at A405T and A499T, respectively. Sequencing of ORF30 in addition to ORFs 11 and
13 identifies clades 10 and 11. Inclusion of ORFs 37, 52 and 76 identifies the remaining clades 1,
3, 5, and 13. This approach has the potential to be used globally as the clades are not specific to Irish
isolates but include viruses from Asia, Australia, North America, and Europe. Furthermore, the assay
could be modified in the future employing a multiplex PCR to amplify several target fragments
simultaneously prior to sequencing. This would be less labour-intensive and more cost-effective.
Neurological disease was associated with viruses from nine of the ten clades identified. Outbreaks
with multiple cases of abortion were also associated with viruses from nine clades but outbreaks with
multiple neurological cases were restricted to viruses from six clades. A significant association between
clade and neurological disease was found (p-value = 0.02) driven by high expression in clades 1 and 3.
Furthermore, the statistical association between clade and hypervirulence was found (p-value = 0.027)
driven by high expression in clades 1 and 8.
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Figure 2. Multi-locus sequence analysis of representative Irish EHV-1 isolates using 38 amino acid differences in 26 open reading frames (ORFs). Amino acid 
differences (n = 38, including triplet in ORF14) between EHV-1 strains Ab4 and V592 and representative Irish isolates across 26 ORFs. Amino acid positions are 
numbered according to V592. Colours are used to highlight different UL clades [35]. EHV-1 representatives from 10 clades are shown. Shading is used to highlight 
amino acid difference at that site. The putative neurological marker at ORF30 variable site N752/D752 is highlighted in grey. The number of isolates with the same 
genotype for each clade is summarised by years, counties, premises, and cases of EHV-1 examined. Neuro indicates number of isolates from cases of neurological 
disease. 1 ND: indicates not determined. 2 Includes repeated samples (n = 3) from the same case. 3 Indicates ORF68 not assigned group. (--- ) represents gap in sequence. 
* represents an Italian isolate. 
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Thirty-five viruses from 31 outbreaks i.e., 13% of the outbreaks included in the study, had the
G2254/D752 change in polymerase gene associated with neuropathogenicity [21]. These viruses
clustered in several different clades; eight from six outbreaks were clade 1, one was clade 3, five were
clade 7, 14 from 13 outbreaks were clade 8, two were clade 9, three from two outbreaks were clade 11,
and two were clade 13 (see Table 1). A statistical association between clade and the G2254/D752
genotype was found (p-value < 0.001) driven by high expression in clades 1 and 8. Eighteen of the
35 G2254/D752 viruses (51.4%) were isolated from cases of neurological disease. The remainder were
from cases of abortion or neonatal foal death. Six were from five outbreaks of multiple abortion. In this
study seven viruses characterised from cases of neurological disease lacked the neuropathogenic
marker, i.e., had the A2254/N752 genotype. However, to the best of our knowledge all were single
cases. The association between the G2254/D752 genotype and neurological disease was found to be
highly significant (p-value <0.001). The odds of developing neurological disease after viral infection
for those with the G2254/D752 genotype was estimated as 27 times greater than for those with
the A2254/N752 genotype (odds ratio (OR) = 26.9; 95% confidence interval (CI): 10–75). Multiple
outbreaks of neurological disease were 38 times more likely than single outbreaks if associated with the
neuropathogenic marker (OR = 38.3; 95% CI: 2–820). Furthermore, there was a statistically significant
association between the G2254/D752 marker and hypervirulent disease expression as defined by
outbreaks involving multiple abortion or neurological cases (p-value <0.001). The odds ratio for the
G2254/D752 genotype and hypervirulence was determined as almost five times greater than with an
A2254/N752 strain (OR = 4.8; 95% CI: 2.2–10.5).
2.2. ORF68
A ~1185 bp nucleotide sequence of ORF68 for 222 isolates representative of 222 EHV-1 outbreaks
over the 28-year period was determined to assess the relationship between ORF68 groups and
clades identified by multi-locus analysis. Sequence analysis of this polymorphic region of ORF68
identified isolates in each of Nugent’s six groups and one of her two unassigned groups (see alignment
Figure 3). ORF68 representative sequences have been deposited in GenBank with accession numbers
MH976701-MH976709. Of the 222 isolates analysed using this grouping system, only one Irish isolate
belongs to group 1. Similar to Ab4, IRL/497/1997 encodes 8 G’s in the homopolymeric tract, giving
rise to a 418 amino acid (aa) long US2 protein compared with 303aa for EHV-1 isolates in other groups.
Twenty-six isolates (11.7%) belong to group 2. The majority of isolates 112 (50.45%) belong to group 3
and have the characteristic SNP T719. However, two previously unidentified nucleotide changes at
SNP A87 and SNP A821 in group 3 viruses may represent two new sub-groups. Twenty-seven (12.16%)
and 20 isolates (9%) belong to groups 4 and 5, respectively. All the group 5 isolates identified had the
additional SNP C626 in addition to the group 5 characteristic SNPs G710 and A713. Twenty-two (9.9%)
isolates belong to the V592-like group 6. A further 14 isolates (6.3%) which contained A629 and T755
SNPs were categorised as belonging to Nugent’s unassigned group.




Figure 3. Regions of sequence variation in ORF68 for representative Irish isolates. Analysis of 222 EHV-1 isolates showed they belong to seven of the groups previously 
described [21]: groups 1–6 and one of the two unassigned groups. N indicates the number of isolates characterised with a particular sequence in the group. Dots indicate 
sequence identity, while group-specific single nucleotide polymorphisms (SNPs) are highlighted. Vertical dashed lines represent breaks in continuous sequence where no 
changes occurred. The numbers above the alignment indicate the nucleotide positions according to the ORF68 sequence of strain Ab4 (group 1), which contains 8 G residues 
in the homopolymeric tract (nucleotides 732–739). Symbol (-) denotes nucleotide deletion and (*) denotes includes one Italian strain. 
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which contains 8 G residues in the homopolymeric tract (nucleotides 732–739). Symbol (-) denotes nucleotide deletion and (*) denotes includes one Italian strain.
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Network analysis (Figure 4) demonstrated that there was no correlation between the sequence
of the polymorphic region of ORF68 and the location of the country where the virus was isolated,
as the majority of Irish isolates clustered with viruses from all over the world. The single Irish group 1
isolate, IRL/497/1997, clusters with four UK isolates (one of which is Ab4) and one Japanese respiratory
isolate in node A. Twenty-five group 2 Irish isolates cluster in node B with viruses from Europe, Japan,
North America, Argentina, and Australia. One hundred and twelve group 3 isolates share the largest
node C with isolates from Europe, North America, and Australia. A further 27 group 4 isolates cluster
with European, North American, Ethiopian, and Indian strains in node D. All 20 Irish group 5 isolates
share node M with North American strains. Node K contains only three strains from the UK, including
reference strain V592 in addition to 22 Irish isolates. Finally, 14 Irish strains belonging to Nugent’s
unassigned group shared node F with a single UK strain and 21 Polish strains only. The single Italian
isolate analysed belonged to node B (group 2).
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Figure 4. Median joining network of global EHV-1 sequences based on a 464 bp alignment of
ORF68 sequences. The network includes 221 Irish isolates, 1 Italian isolate and 219 EHV-1 ORF68
international sequences retrieved from GenBank (see Supplementary Table S4 for sequence information).
Nodes, labelled with capital letters (A to Y), represent the same ORF68 sequence and are coloured
based on the geographical origin of the sample. The area of each circle is in proportion to the frequency
of isolates sharing the same genotype. Hatch marks (|) represent segregating sites. Abbreviations:
UK&W.Europe: United Kingdom and Western Europe; NAmer: North America; AustraliaNZ: Australia
and New Zealand.
There was correlation of ORF68 groups and clades identified by multi-locus analysis. The single
ORF68 group 1 isolate IRL/497/1997, which is similar to Ab4, has G8 in the homopolymeric tract,
clustered with clade 1 viruses. Within ORF68 group 2 there were representatives from clades 1, 3,
5, and 13. Group 3 contained all the clade 7 viruses and 10 of the 24 clade 11 viruses characterised.
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Six clade 11 viruses had an additional SNP A87 which was absent in clade 7 viruses. Group 4 contained
all clade 8 and clade 10 viruses identified. Groups 5 and 6 contained clade 6 and 9 viruses, respectively.
The unassigned group described by Nugent et al. (2006) [21] with SNPs A629 and T755 was composed
of 14 clade 11 viruses.
3. Discussion
The present study is the first to document the molecular characterisation of EHV-1 clinical isolates
in Ireland over a 28-year period. Two hundred and sixty-nine viruses detected in Ireland and a further
three viruses isolated in Italy were included in the multi-locus analysis. Our investigation established
that genetic characterisation has the potential to be a useful aid in the management of EHV-1 outbreaks,
based on identification of the G2254/D752 polymerase genotype, the UL clade assignation, and to
a lesser extent, ORF68 sequencing.
Multi-locus typing of EHV-1 was initiated by Nugent et al. (2006) [21] and extended in this study
to allow comparison to recently proposed UL clades [35]. In the original multi-locus study, analysis
of a panel of twenty-five isolates (12 neurological and 13 non-neurological) using the amino acid
differences between EHV-1 reference strains Ab4 and V592 led to the proposal that ORF68 analysis
could be used for distinguishing isolates without having to type multiple loci [21]. Consequently,
multi-locus analysis has not been widely used by other investigators who have concentrated on
ORF68 sequencing. In this study, multi-locus typing of 272 EHV-1 isolates established a correlation
to 11 of the 13 EHV-1 clades proposed by the recent UK genotyping study [35]. The 272 isolates
characterised clustered in 10 of the 11 clades. Our results concur with those of Bryant et al. (2018) [35]
in demonstrating that clade 7 viruses predominate, and that simultaneous co-circulation of clades
occurs in Ireland. In the next generation sequencing (NGS) study by Bryant et al. (2018) [35] network
analysis suggested that recombination had occurred between EHV-1 strains. This has also been
observed in herpes simplex virus 1 (HSV-1) strains [36]. Furthermore inter-species recombination has
been detected in field samples between EHV-1 and EHV-4 [34,37], EHV-1 and EHV-9 [38], and between
EHV-1 and EHV-8 [35]. Thus, although the genotyping method based on the targeted multi-locus
approach used in this study and also recently developed for VZV [39] may be more practical than
NGS for surveillance purposes, it has the limitation that it does not allow the detection of possible
recombination crossovers in the unanalysed parts of the genome [40]. Whole genome sequencing
(WGS) of viruses is increasingly important in clinical settings but is not yet routinely used in the
majority of veterinary diagnostic laboratories. As sequencing costs continue to decrease, specialised
bioinformatic resources become more accessible and methods are standardised, WGS using NGS
methods is likely to be more widely applied in veterinary medicine providing molecular epidemiology
studies greater accuracy [41]. Meanwhile however, targeted PCR amplification and Sanger sequencing
offer a rapid and robust alternative for the detection of virus variants. This study indicated that analysis
of a SNP identifies viruses of the most common EHV-1 clade in the UK and Ireland, and that only six
ORFs need to be targeted to discriminate between ten clades.
In this study the multi-locus analysis proved very useful to support or negate the epidemiological
data in the tracking of virus between selected premises. Viruses from the same outbreak had identical
profiles whereas viruses identified on the same premises in different years were rarely identical
suggesting reintroduction rather than reactivation or persistent circulation. In three outbreaks on
premises with an epidemiological link the viruses had identical profiles. This included a case of
suspected reactivation of virus from an outbreak in the previous year in a different province. In addition
to providing support for epidemiological links the multi-locus analysis also provided conflicting
evidence that a premise with multiple neurological cases was the source of virus linked to a single case
on another premises.
In the future it is envisaged that molecular typing will become routine in our laboratory and
as several of the EHV-1 clades are not geographically restricted, this approach can be used in other
countries. Molecular evidence corroborating equestrian events or specific premises as the source
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of virus will assist in the implementation of targeted movement restrictions, quarantine and other
control measures. The results of such analysis are not proof of a causal link but add strength and
depth to a clinical advisory service. If for example, viruses of the same clade are isolated from cases
on different premises linked directly or indirectly to return of horses from a training centre or public
stud farm it becomes incumbent on the owner of that centre or farm to communicate a possible
risk to clients. In terms of clinical management an informed decision may be taken to quarantine
horses on the public premises until there is no further evidence of circulating virus or clients may
implement extra biosecurity measures in relation to transport, isolation and monitoring of horses
returning from that centre. Demonstration that repeated outbreaks of EHV-1 on individual premises
are due to viruses of different clades can also contribute to clinical management. Owners of premises
that suffer repeated incidences of EHV-1 associated disease frequently focus on reactivation of latent
virus and identification and removal of a “carrier”. Molecular evidence to the contrary facilitates the
introduction of improved management practices with respect to vaccination, separation of broodmares
from younger stock and sport horses and temporary isolation of visiting mares.
Since Nugent et al. (2006) [21] put forward the hypothesis that variants with the G2254/D752
substitution in the DNA polymerase have increased likelihood of association with neuropathogenicity,
there has been international focus on the characterisation of the genotypes of EHV-1 isolates and
allelic discrimination assays have been widely used to distinguish between neuropathogenic and
non-neuropathogenic strains [42,43]. Many studies concentrate on the retrospective investigation
of archived viruses and the prevalence data generated must be interpreted with caution due to
sampling and storage bias. In this study, 35 of 272 viruses from 238 outbreaks had the G2254/D752
genotype suggesting a prevalence of 12.9% in Ireland. However, this prevalence may reflect sample
bias for the isolates chosen for characterisation, prior to the introduction of routine genotyping
in 2005. Thus, the true prevalence is likely to be nearer 9% calculated from the years 2005–2017.
The findings indicate that the vast majority of Irish viruses have the A2254/N752 genotype. It has
been demonstrated in some studies that horses infected with a G2254/D752 variant such as Ab4
show higher levels of virus shedding than horses infected with the A2254/N752 variant such as
V592 [16,19,44–46]. Subsequently it was suggested that this may indicate a selective advantage of the
G2254/D752 strains which could favour an increase in prevalence such as that reported in the United
States from 3.3% in the 1960s to 19.4% since the year 2000 [26,47,48]. In recent years there has been an
increase in the number of severe EHM outbreaks reported in other countries including France which
subscribes to a Tripartite Agreement for the free movement of horses without health checks between
Ireland, France, and the UK [49,50]. However, neither a parallel increase in the incidence of EHM nor
an increase in the detection of the G2254/D752 variant has been observed in Ireland. The abundance
of A2254/N752 variants in the majority of field studies globally suggests that the proposed selective
advantage of the G2254/D752 variant has not resulted in strain displacement in the wider equine
population [25,35,48,49,51,52].
Viraemia is essential for the spread of the virus from peripheral blood mononuclear cells
(PBMCs) to endothelial cells lining the blood vessels in the CNS or the pregnant uterus [11,53].
Horses experimentally infected with neuropathogenic strains develop a cell-associated viraemia
greater in magnitude and longer in duration than with non-neuropathogenic virus strains [16,19,54]
and G2254/D752 strains are more successful in the infection of PBMCs and the establishment of
viraemia compared to A2254/N752 strains [46,55]. In this study there was a statistically significant
association between viruses of the G2254/D752 genotype and hypervirulent disease expression as
defined by outbreaks involving multiple abortions or neurological cases. International findings
related to the association of EHV-1 genotype with pathogenic phenotypes vary. Nugent et al. (2006)
examined 131 EHV-1 isolates from nine countries [21]. Of the 49 neurological isolates examined,
42 (86%) had the G2254/D752 genotype whereas 78/82 (95%) of non-neurological isolates had
the A2254/N752 genotype. Following this study several large outbreaks of EHM documented in
the literature were associated with the G2254/D752 genotype including outbreaks in Croatia [56],
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France [49], Germany [57,58], Canada [44] and the first reported outbreak of EHM in New
Zealand [59]. However, studies in other countries showed that not all horses with EHM were
infected with a strain of the G2254/D752 genotype and that A2254/N752 variants are also associated
with neurological disease [24,26,52,60]. Similarly, the G2254/D752 genotype was associated with
non-neurological/abortion outbreaks in Europe [25,51,60] and the Americas [48,52]. In this study,
the likelihood of neurological disease was 27 times greater when the causal virus was of the
G2254/D752 genotype rather than the A2254/N752 genotype. However, the onset of neurological
disease cannot be fully attributed to this virus polymorphism and it is suggested that other viral
pathogenicity determinants such as glycoprotein D and host factors such as age, gender, immunity and
hormonal status may contribute to disease severity [46,61]. More recently Brosnahan et al. (2018) [62]
investigated the role of host genetics and identified a SNP in an intron of a platelet-related gene
associated with EHM.
Since 2006, when it was first proposed by Nugent et al. (2006) [21] that the ORF68 polymorphic
region was a putative molecular marker for epidemiological studies, this region has been commonly
used for genotyping of EHV-1 isolates in different countries: Australia [24], Ethiopia [31], Hungary [30],
India [29], Japan [33], and Poland [32]. The study by Nugent et al. (2006) [21] identified six major
groups (1–6) and two unassigned groups based on analysis of 106 global isolates and proposed that
certain strain groups were geographically restricted. Sequence analysis in this study showed that
all Irish isolates segregated into the six groups and one of the two unassigned groups described
by Nugent et al. (2006) [21]. The majority of viruses characterised internationally also support this
ORF68 grouping system. Cuxson et al. (2014) classified 52 Australian isolates as group 2 or 3 and two
as group 5 [24]. Ninety-one Ethiopian isolates were restricted to group 4 [31], eight Indian isolates
clustered within groups 4 and 5 [29] and a Japanese isolate was classified as group 2 [33]. However,
several of these studies also reported a small number of viruses that could not be classified within
the original proposed groups [24,29,33]. Studies in Eastern Europe identified further polymorphism.
A study of 38 viruses from cases of abortion in Poland assigned three to group 3, four to group 4, and
22 to one of the unassigned groups [21] but nine were classified in two novel groups [32]. Similarly,
in Hungary only 23 of 35 isolates fitted with the originally described groups (groups 2, 3, and 4)
and four new groups were proposed [30]. None of the viruses in this study grouped in the novel
groups proposed.
The original hypothesis that ORF68 groups are geographically restricted is not supported by the
results of our study or those of other investigators. For example, Nugent et al. (2006) [21] found that all
group 5 isolates came from outbreaks in North America; however, 9% (20/222) of Irish isolates belong
to this group, which has been demonstrated to include viruses from Australia [24] and India [29].
Network analysis of Irish isolates with international strains showed that Irish isolates clustered within
7 nodes with isolates from the several different geographic regions. In agreement with the conclusions
from studies in Hungary and Poland this suggests that ORF68 is not a suitable global marker [30,32].
However, this type of strain variation has been demonstrated to be a useful adjunct to epidemiological
data when investigating disease outbreaks on multiple premises [56,57,63]. In this study ORF68 genetic
analysis of Irish isolates substantiated virus tracking by multiple-locus typing. However, analysis of
222 isolates by both ORF68 sequence and multi-locus typing indicated that although both are useful
molecular epidemiological tools multi-locus typing is more accurate. The ORF68 grouping system
groups together some viruses from different clades which are readily distinguishable by multi-locus
analysis. As more EHV-1 strains are sequenced internationally, additional polymorphisms and new
clades are likely to be identified, with the potential to further refine epidemiological investigations in
identifying transmission pathways.
In conclusion, this is the first study to explore the genetic diversity of EHV-1 in Ireland, the third
largest producer of thoroughbred foals in the world [64]. The contribution of genetic characterisation
to our understanding of viral pathogenesis, development of diagnostics, implementation of
evidence-based management strategies, and predictions of likely outcome and disease spread is
Pathogens 2019, 8, 7 14 of 21
increasing. The data relating to over 250 EHV-1 isolates presented here adds depth to our knowledge
of circulating genotypes and illustrates that tracking of virus by genetic analysis when used in
combination with epidemiological data gives valuable insights and support for targeted preventive
measures. An example of a targeted preventive measure is where on acceptance of data implicating
mare sales as the transmission pathway for EHV-1 abortions at geographically disparate locations,
a sales company introduces a new condition of sale that all pregnant mares are vaccinated against
EHV-1. Consistent with previous studies globally, our results indicated that infection with a strain of
the G2254/D752 genotype will not inevitably result in neurological disease. Nevertheless, the strong
association with hypervirulence observed in this study suggests that it would be of benefit to
veterinarians to be aware that horses in their care are at increased risk of developing EHM or multiple
abortions when a virus of this genotype is detected.
4. Materials and Methods
4.1. Viruses
EHV-1 viruses archived at the Virology Unit of the Irish Equine Centre between 1990 and 2017
were retrieved along with the clinical histories available. The clinical samples, which had been stored
at −70 ◦C, included nasal secretions and tissue homogenates from cases of neurological disease,
abortion, and neonatal foal deaths. Two hundred and sixty-nine isolates originated from Ireland.
Three isolates from two severe abortion outbreaks in Italy were also included. The samples were
retrospectively allocated a unique reference number derived from the country, laboratory number
and year of collection. A summary of the numbers of isolates analysed in this study is given in
Table 3. An overview of all samples included in this study is given in Supplementary Table S1.
Two hundred and seventy-two isolates (269 horses) from 238 outbreaks on 220 premises were
genetically characterised by multi-locus typing. Representative viruses from 222 of these 238 outbreaks
were also characterised by ORF68 sequencing.
Table 3. Summary of the numbers of EHV-1 isolates genotyped.
Disease Expression Isolates Horses Outbreaks Premises 2 Multi-Locus Typing ORF68 Typing
Respiratory 3 3 3 3 3 3
Single abortion/
neonatal foal death 171 170
1 170 163 171 164
Multiple abortion/
neonatal foal death 73 71 43 42 73 38
Single neurological disease 11 11 1 11 11 11 7
Multiple neurological disease 14 14 11 11 14 10
Total 272 269 238 220 2 272 222
1 One mare is categorised under single abortion and single neurological disease expression. Isolate IRL/766/2008
was collected when she exhibited neurological signs and isolate IRL/155/2008 was collected from her aborted
foetus 11 weeks later. 2 Some premises experienced EHV-1 outbreaks in different years therefore the total number
of outbreaks.
The majority of the viruses were recovered from clinical samples: nasal secretions from
respiratory/neurological disease (n = 10) and tissues (lungs, liver, spleen, allantochorion, and
amniotic cord) from cases of abortion/neonatal foal death (n = 237). Twenty-five samples with a low
concentration of virus (brain tissue from cases of neurological disease (n = 2), nasal swabs (n = 14)
and multiple tissues (n = 9)) were amplified by a single passage in cell culture. For culture isolation of
these viruses, 25 cm3 tissue culture flasks of near confluent rabbit kidney (RK-13) cells were inoculated
with 0.5 ml tissue homogenate/nasal fluid. The cells were maintained in 5 ml of maintenance medium
(supplemented with 2% foetal calf serum) at 37 ◦C in an atmosphere of 5% CO2 [65]. The monolayer
was examined for the presence of cytopathic effect (CPE). Where sequences were compared between
DNA samples prepared directly from the sample and tissue culture isolates from the same outbreak,
they were found to be identical (n = 10).
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4.2. Extraction of DNA
DNA was extracted from 200 µL of tissue homogenates/nasal secretions/RK-13 infected cells
using the QIAamp DNA Mini kit (Cat No: 51306, Qiagen) according to the manufacturer’s instructions.
Alternatively, DNA was extracted from 100 µL of sample by an automated method using the Kingfisher
Flex Magnetic Particle Processor instrument (Thermo Scientific) with the LSI MagVet Universal
Isolation Kit (Life Technologies) as per the kit manufacturer’s guidelines.
4.3. PCR of multiple loci of EHV-1
The complete genome sequences of Ab4 (AY665713.1) and V592 (AY464052.1) were aligned using
ClustalW [66]. Non-synonymous changes were identified between the two genomes in the protein
coding regions (as described previously [21]) and primers were designed with similar annealing
temperatures to amplify the loci of sequence variation between Ab4 and V592 (see Table 4). Primers
were not designed for ORF24 and ORF71 as these contained repeat regions considered to be of
limited use for epidemiological studies [21]. Primer sequences are detailed in Supplementary Table S5.
The reaction component (50 µL) for amplification of the target sequences consisted of 2.5 U GoTaq
Hot Start Polymerase (5 U/µL) (catalogue no. M5001, Promega), 1X GoTaq Flexi Buffer, 2 mM MgCl2
solution, 0.2 mM dNTP Mixture (Applied Biosystems), 0.4 of µM each primer, 5 µL template DNA,
and nuclease free water (NFW). The cycling conditions were as follows: an initial denaturation at
95 ◦C for 5 min followed by 40 cycles of denaturation at 95 ◦C for 30 s, annealing at 57 ◦C for 45 s,
elongation at 72 ◦C for 2 min, and final extension at 72 ◦C for 5 min.
Table 4. Non-synonymous sites between EHV-1 Ab4 and V592 used for multi-locus analysis.
AA Variation
ORF AA Position 1 Ab4 V592 Other 2
2 59 G D /3
5 114 G V /
8 114 D N /
11 189 Q K /
11 235 R R M
13 305 S L /
13 405 A A T
13 460 A T /
13 492 E E K
13 493 T T I
13 499 A A T
14 618–620 -4 PSR /
14 628 R R K
14 692 S S N
15 166 D N /
22 430 S P /
29 12 T K /
30 752 D N /
30 990 E K /
31 90 N S /
32 42 S L /
33 15 N H /
33 976 N D /
34 66 D G /
36 47 S R /
37 265 A V /
39 440 S L /
40 196 R H /
42 1275 K R /
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Table 4. Cont.
AA Variation
ORF AA Position 1 Ab4 V592 Other 2
45 427 E G /
46 140 F S /
50 367 P S /
52 386 A V /
57 804 K R /
73 122 A V /
76 128 F S /
1 Amino acid positions are numbered according to V592 amino acid sequence. 2 Refers to additional amino acid
coding changes observed in amino acid alignments of other EHV-1 strains. 3 Not applicable. 4 Gap in sequence.
Post-amplification 5 µL of each PCR product was analysed on a 1.2% agarose gel (Sigma)
stained with 0.003% Sybersafe (Invitrogen). Reactions were purified using the QIAquick PCR
Purification kit (catalogue no. 28106, Qiagen) or the QIAquick Gel Extraction kit (catalogue no. 28706,
Qiagen). Purified PCR products were sequenced using Sanger dideoxynucleotide sequencing
technology (MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; GATC-Biotech,
Cologne, Germany).
4.4. Multi-Locus Sequence Analysis
Nucleotide sequences obtained from targeted multi-locus sequence analysis were aligned
to individual ORFs of reference strains Ab4 (neuropathogenic, G2254/D752 strain) and V592
(non-neuropathogenic, A2254/N752 strain) using Seqman. Comparative analysis of predicted partial
amino acid sequences was carried out for each isolate by using the ClustalW [66] accessory application
in BioEdit sequence alignment editor version 7.2.5 [67]. Twenty-eight complete and 78 partial EHV-1
genome sequences which had been included in the study by Bryant et al. (2018) [35] were mined from
GenBank [68] (Supplementary Table S2). Nucleotide sequences of individual ORFs were translated
using ClustalW implemented in Bioedit. Multiple amino acid sequence alignments were produced for
individual ORFs with Ab4 as a reference sequence. Positions of amino acid sequence variation were
recorded and tabulated for the sequenced isolates and EHV-1 genome sequences.
Thirty-one non-synonymous substitutions between Ab4 and V592 in 26 ORFs in UL and US
were examined. Amino acid alignments of complete genome sequences and isolates sequenced in
this study identified seven additional substitutions to those in Ab4 and V592 in ORFs 11 (R235M),
13 (A405T, E492K, T493I, A499T), and 14 (R628K, S692N) which were also included in the analysis.
A concatenated amino acid sequence based on these 38 amino acid differences was constructed for
each isolate and the EHV-1 genome sequences. The resulting 38aa artificial peptide sequences (n = 321)
were aligned using ClustalW (Supplementary Figure S1). Representative sequences (n = 126, including
96 isolates sequenced in this study) were aligned in MUSCLE [69] implemented in MEGA7 version
7.0.14 [70]. Phylogenetic analysis of these 126 sequences was inferred by the Maximum Likelihood
method based on the Jones Taylor Thornton (JTT) matrix-based model [71] with bootstrap values
determined over 100 iterations. The topology of the tree was examined for UL clade resolution based
on the study of Bryant et al. (2018) [35].
4.5. PCR of EHV-1 ORF68
PCR primers were designed to amplify ORF68 (US2) (detailed in Table 5) based on EHV-1 reference
sequences Ab4 (GenBank accession AY665713.1) and V592 (GenBank accession AY464052.1) using the
online application Primer3 [72]. Amplification was performed using the G-Storm (Gene Technologies)
with the PCRx Enhancer System (catalogue no. 11495-017, Invitrogen) which is specific for the
amplification of problematic and/or GC-rich templates. The reaction component consisted of 1X
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PCRx Amplification Buffer, 1.5 mM MgSO4, 2X PCRx Enhancer Solution, 0.4 µM each primer, 5 U of
Taq DNA Polymerase (5 U/µL, Invitrogen), 0.2 mM dNTP Mixture (Applied Biosystems), 10 µL of
template DNA, and nuclease free water to a final volume of 50 µL. Initial denaturation was carried out
at 95 ◦C for 5 min, followed by amplification with 40 cycles of 95 ◦C for 30 s, 50 ◦C for 1 min, 72 ◦C for
2 min, and a final elongation at 72 ◦C for 10 min.
Table 5. Primers used for ORF68 amplification and sequencing.
Primer Description Primer Sequence 5′ to 3′ Nucleotide Position on Strain Ab4
Forward PCR ATGGGTGTGGTCTTAATTAC 126275–126256
Reverse PCR GACACCGCCTGAAGTAGGAG 124963–124982
68R2 Sequencing ACCGTTGAGCATAATCATCC [21] 125730–125710
68S1 Sequencing GAAGATAGAATGGGTGTGAG [21] 125999–125979
4.6. ORF68 Sequence Analysis
The four overlapping sequence regions of the 1313bp ORF68 amplicon were assembled for each
isolate using Seqman Version 5.01 (DNASTAR). Nucleotide sequence alignments were performed using
the ClustalW [66] application in BioEdit [67]. Sequences were aligned using Ab4 strain as a reference to
identify variable positions and perform grouping of the isolates as per Nugent et al. (2006) [21]. Isolates
from 222 of the 238 outbreaks, defined as an occurrence of one or more cases in an epidemiological
unit, were included in the analysis. Incomplete ORF68 sequence data was obtained for 16 of the
238 outbreaks which necessitated exclusion from the analysis. ORF68 sequence data for a further
219 EHV-1 isolates were retrieved from GenBank (sequence information can be found in Supplementary
Table S4). The ORF68 alignment of 464 bp in length was converted to nexus file format using Seqret
in EMBOSS [73]. An international median-joining haplotype network of EHV-1 ORF68 sequences,
colour-coded by geographic location, was constructed in PopART version 1.7 [74] as described
previously for Polish EHV-1 strains [32].
4.7. Statistical Methods
A chi-squared test for association and proportion was used to test the null hypothesis that
there was no difference in the relative proportions of the G2254/D752 genotype between: isolates
originating from neurological and non-neurological outbreaks, isolates originating from single cases of
neurological disease and outbreaks with multiple neurological cases, and isolates originating from
hypervirulent disease expression defined as multiple abortions or multiple cases of neurological
disease, and those from sporadic cases. The same statistical test was used to investigate the statistical
significance of: the G2254/D752 genotype, hypervirulent disease expression, and neurological disease,
across the clades where Irish strains resided. Odds ratios for neurological disease, hypervirulent disease
expression, and multiple neurological cases with the putative neurological marker were estimated
with a 95% confidence interval. The data was summarised in 2 × 2 contingency tables and analysis
was conducted in the R statistical software package version 3.5.1. The statistical significance was set at
α = 0.05.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/8/1/7/s1,
Figure S1: Alignment of 322 EHV-1 artificial peptide sequences; Table S1: Summary of EHV-1 strains genotyped
and listed in order of UL clades; Table S2: Accession codes for EHV-1 sequences used in alignment; Table S3:
Premises where more than one isolate was characterised by multi-locus sequence typing; Table S4: Details of
EHV-1 ORF68 sequences used in network analysis; Table S5: Primer sequences used for multi-locus amplification.
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